BridgeBio Pharma BBIO License — Receivable Current From Licensing And Collaboration Agreements
Discontinued — last reported Q3 '21
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept bbio:ReceivableCurrentFromLicensingAndCollaborationAgreements.
The official record: BridgeBio Pharma’s 10-Q, filed November 4, 2021, on SEC EDGAR. View the filing →
Ask your AI about BridgeBio Pharma's license — receivable current from licensing and collaboration agreements.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BridgeBio Pharma's license — receivable current from licensing and collaboration agreements?
- BridgeBio Pharma (BBIO) reported license — receivable current from licensing and collaboration agreements of $0 in Q3 2021.
- What does license — receivable current from licensing and collaboration agreements mean?
- The amount of money currently owed to the company by licensing partners that is expected to be paid within one year.
- How do you interpret license — receivable current from licensing and collaboration agreements?
- An increase indicates higher near-term cash inflows from partnerships, while a decrease may suggest faster collection cycles or a reduction in current-period licensing activity.
- How does license — receivable current from licensing and collaboration agreements compare across companies?
- Comparable to 'Accounts Receivable' or 'Trade Receivables' specifically tied to collaboration and licensing segments in the biotech industry.